• Salix Pharmaceuticals Ltd., of Raleigh, N.C., priced an offering of $600 million of 1.5 percent convertible senior notes due March 15, 2019, to institutional buyers and granted the buyers an option to purchase up to an additional $90 million in notes to cover overallotments. The notes are convertible into cash, shares of Salix common stock or a combination of the two, at Salix's election.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST